These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12151869)

  • 21. Mechanisms of obesity-induced hypertension.
    Kotsis V; Stabouli S; Papakatsika S; Rizos Z; Parati G
    Hypertens Res; 2010 May; 33(5):386-93. PubMed ID: 20442753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity-associated hypertension: new insights into mechanisms.
    Rahmouni K; Correia ML; Haynes WG; Mark AL
    Hypertension; 2005 Jan; 45(1):9-14. PubMed ID: 15583075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of hypertension in obese patients].
    Comte-Perret S; Giusti V; Wuerzner G
    Rev Med Suisse; 2013 Sep; 9(397):1622, 1624-6. PubMed ID: 24073473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of hypertension and kidney disease in obesity.
    Hall JE; Brands MW; Henegar JR
    Ann N Y Acad Sci; 1999 Nov; 892():91-107. PubMed ID: 10842655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neural mechanisms and management of obesity-related hypertension.
    Esler MD; Eikelis N; Lambert E; Straznicky N
    Curr Cardiol Rep; 2008 Nov; 10(6):456-63. PubMed ID: 18950554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary hypertension: obesity and the metabolic syndrome.
    Singer GM; Setaro JF
    J Clin Hypertens (Greenwich); 2008 Jul; 10(7):567-74. PubMed ID: 18607142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of abnormal renal sodium handling in obesity hypertension.
    Hall JE
    Am J Hypertens; 1997 May; 10(5 Pt 2):49S-55S. PubMed ID: 9160781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension.
    Engeli S; Sharma AM
    J Mol Med (Berl); 2001; 79(1):21-9. PubMed ID: 11327100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of leptin and central nervous system melanocortins in obesity hypertension.
    da Silva AA; do Carmo JM; Hall JE
    Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):135-40. PubMed ID: 23299052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms mediating renal sympathetic nerve activation in obesity-related hypertension.
    Chen W; Leo S; Weng C; Yang X; Wu Y; Tang X
    Herz; 2015 Apr; 40 Suppl 2():190-6. PubMed ID: 24609799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Obesity: a common prime mover of chronic activation of the sympathetic nervous system and the renin-angiotensin system in systemic hypertension?
    Szelényi Z
    J Appl Physiol (1985); 2010 Dec; 109(6):2008-9. PubMed ID: 21188835
    [No Abstract]   [Full Text] [Related]  

  • 32. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches.
    Reisin E; Jack AV
    Med Clin North Am; 2009 May; 93(3):733-51. PubMed ID: 19427502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal consequences of obesity.
    Naumnik B; Myśliwiec M
    Med Sci Monit; 2010 Aug; 16(8):RA163-70. PubMed ID: 20671624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the sympathetic nervous system in obesity-related hypertension.
    da Silva AA; do Carmo J; Dubinion J; Hall JE
    Curr Hypertens Rep; 2009 Jun; 11(3):206-11. PubMed ID: 19442330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity-hypertension: emerging concepts in pathophysiology and treatment.
    Mathew B; Patel SB; Reams GP; Freeman RH; Spear RM; Villarreal D
    Am J Med Sci; 2007 Jul; 334(1):23-30. PubMed ID: 17630587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity and hypertension.
    Mikhail N; Golub MS; Tuck ML
    Prog Cardiovasc Dis; 1999; 42(1):39-58. PubMed ID: 10505492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a rationale for angiotensin blockade in the management of obesity hypertension?
    Sharma AM
    Hypertension; 2004 Jul; 44(1):12-9. PubMed ID: 15173127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Animal models in obesity and hypertension.
    Segal-Lieberman G; Rosenthal T
    Curr Hypertens Rep; 2013 Jun; 15(3):190-5. PubMed ID: 23536127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity-hypertension: an ongoing pandemic.
    Francischetti EA; Genelhu VA
    Int J Clin Pract; 2007 Feb; 61(2):269-80. PubMed ID: 17263714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The sympathetic nervous system alterations in human hypertension.
    Grassi G; Mark A; Esler M
    Circ Res; 2015 Mar; 116(6):976-90. PubMed ID: 25767284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.